Key Development
Hanoi’s health authority has withdrawn 30 Class A and B medical-device standard declarations. But this should not be interpreted as a conventional product-quality recall. The regulatory issue centers on whether the products’ intended uses were appropriate for the Class A/B declaration pathway.
The affected filings span nasal and throat sprays, topical products, a CO2 laser system, skin-therapy equipment, a low-temperature sterilizer and bedside leukocyte filters. The declarations date from 2022 through 2026, with several having been published only in mid-September 2026 before withdrawal. Hanoi’s Department of Health cited inappropriate intended use for declaration as Class A or B medical devices.
Under Vietnam’s current framework, Class A devices are considered low risk and Class B devices low-to-moderate risk. Classification must be based on risk and intended use; where one intended use could fall into multiple risk levels, the higher classification applies.
Why It Matters
- Intended use is regulatory architecture, not marketing copy. It can determine whether a product qualifies as a medical device and which risk class applies.
- The A/B pathway emphasizes declaration and rapid publication. Once the required filing is received, the provincial health authority publishes the declaration number and relevant dossier information, making company accountability and subsequent regulatory review crucial safeguards.
- The mixture of old and very recent filings suggests two forms of enforcement: retrospective portfolio cleanup and faster detection of newer questionable classifications.
- This is not an isolated precedent. Hanoi withdrew 280 Class A/B declarations in 2024 over issues including products not fitting the medical-device definition or having inappropriate intended uses/classification.
Healthcare Insight Analysis
Healthcare Insight believes the key development is not the number 30.
It is what the withdrawals reveal about the regulatory model.
For lower-risk medical devices, Vietnam has deliberately created a relatively streamlined market-entry mechanism. That reduces unnecessary administrative friction, but it also shifts substantial responsibility toward the company placing the product on the market.
In that system, post-declaration review is not a secondary control. It is the mechanism that balances faster entry.
This creates a business issue that medtech companies can easily underestimate: claim architecture.
Products that appear physically similar can follow different regulatory pathways depending on what the manufacturer says they are intended to do.
A claim to clean, protect or support a physiological function is not necessarily equivalent to a claim to diagnose or treat disease. Likewise, an energy-based skin device marketed for cosmetic surface care can create a different regulatory question from one intended to treat a medical condition.
Regulatory strategy therefore needs to begin before commercial teams finalize claims, labels and instructions for use.
That changes the traditional compliance workflow.
Instead of:
product → marketing claim → regulatory filing
the safer sequence becomes:
product function → intended use → risk classification → evidence requirement → claim architecture → commercialization.
The commercial consequences of getting this wrong can be substantial.
Withdrawal may require the business to reassess classification, change the intended use, amend documentation or pursue another market-access route before continued commercialization. Vietnam’s framework also specifically provides for withdrawal where incorrect classification reduces a device’s risk level, with responsibilities falling on classification entities and circulation-number holders.
Transparency makes this even more important.
Medical-device filings are publicly searchable through the Ministry of Health portal. That means regulatory status can be checked not only by authorities, but also by hospital procurement teams, distributors and competitors.
As the market matures, regulatory cleanliness becomes a commercial asset.
A device with unstable regulatory status can create tender disruption, stranded inventory and distributor risk far exceeding the cost of robust classification work before launch.
Market Implications
Manufacturers and importers: regulatory review should begin with intended use and claims, rather than functioning as a final filing exercise.
Distributors: due diligence should move beyond asking whether a declaration number exists to verifying whether its classification remains defensible and valid.
Hospitals: procurement teams may increasingly need real-time verification of regulatory status before tenders and purchasing decisions.
Regulatory services: value is likely to migrate from transactional dossier submission toward classification strategy, claim review and lifecycle compliance.
ANALYTICAL MATRIX
| Dimension | Current Signal | Business Implication | Key Risk |
| Classification | 30 Class A/B declarations withdrawn | Classification is an active control point | Wrong market-access pathway |
| Intended use | Central reason for withdrawal | Claims affect regulatory status | Regulatory–marketing mismatch |
| Post-market review | 2022–2026 filings reassessed | Compliance is continuous | Legacy portfolio exposure |
| Market entry | Streamlined A/B declaration | Faster initial access | Access can be reversed |
| Procurement | Status is publicly searchable | Greater market transparency | Tender and inventory disruption |
Two useful corporate KPIs are therefore not simply time to obtain a declaration number, but the proportion of the portfolio surviving post-market regulatory review without reclassification or withdrawal, and time required to remediate regulatory issues when they arise.
If enforcement continues in this direction, the competitive advantage will not belong to the company that reaches the market fastest. It will belong to the company that can reach the market quickly and still have its regulatory position survive scrutiny afterward.